UNSPSC 51141579: Stiripentol

This classification denotes an anticonvulsant with the molecular formula C14H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R02XOT8V8I, chemically known as 4,4-dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol but generally known as stiripentol, which bears US NIH Compound Identifier 5311454. European Medicines Agency schedules Stiripentol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10654MIG.

UNSPSC 51141579 Stiripentol, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The three most recent solicitations tracked under this code — a naloxone and drug deactivation systems purchase from Seminole County, Florida; a therapeutic pharmacy initiative direct-to-manufacturer prescriptions RFI from the Texas Health and Human Services Commission; and a multi-source generic pharmaceuticals and OTC products RFP from the Minnesota Multistate Cooperative Purchasing Alliance — involve naloxone, pharmacy benefit program management, and generic pharmaceuticals broadly, none of which constitute stiripentol specifically. Stiripentol is a rare antiepileptic drug with narrow clinical application, and the recent opportunities show state and local governments purchasing emergency opioid-reversal agents, conducting market research on prescription fulfillment models, and procuring commodity generic drugs through cooperative purchasing vehicles. The code appears to reflect a tagging mismatch rather than active procurement demand for stiripentol itself.

Recent activity clusters in Florida, Texas, and Minnesota, driven by diverse issuing bodies — a county health authority, a state HHS commission, and a multi-state cooperative purchasing alliance. The Seminole County IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year term with one-year renewal option. The Texas HHS RFI (HHS0017013, posted April 3, 2026) gathered vendor intelligence on direct-to-manufacturer prescription contracting for self-insured health plans and state agencies. The MMCAP RFP (S1070000015802, due March 26, 2026) established multi-award generic pharmaceutical and OTC product supply contracts across participating state and local facilities, with products available by May 15, 2026, and contracts effective July 1, 2026. Vendors in cooperative purchasing opportunities must comply with cGMP and DSCSA certifications, maintain relationships with authorized wholesalers, and meet specific insurance and compliance thresholds. No relevant activity under the stiripentol code itself is present in the recent record.